The Impact of the Course of Disease before Botulinum Toxin Therapy on the Course of Treatment and Long-Term Outcome in Cervical Dystonia

被引:5
作者
Hefter, Harald [1 ]
Schomaecker, Isabelle [1 ]
Schomaecker, Max [1 ]
Rosenthal, Dietmar [1 ]
Samadzadeh, Sara [1 ]
机构
[1] Dept Neurol, Moorenstr 5, D-40225 Dusseldorf, Germany
关键词
cervical dystonia; natural history; course of disease; CoDB-graph; botulinum toxin therapy; long-term outcome; patient's drawing; SPASMODIC TORTICOLLIS; MOVEMENT-DISORDERS; NATURAL-HISTORY; EFFICACY; EPIDEMIOLOGY; SATISFACTION; PREVALENCE; MANAGEMENT; FAILURE; SAFETY;
D O I
10.3390/toxins13070493
中图分类号
TS2 [食品工业];
学科分类号
0832 ;
摘要
This study analyses the influence of the course of the disease of idiopathic cervical dystonia (CD) before botulinum toxin (BoNT) therapy on long-term outcomes. 74 CD-patients who were treated on a regular basis in the botulinum toxin outpatient department of the University of Dusseldorf and had received at least 3 injections were consecutively recruited after written informed consent. Patients were asked to rate the amount of change of CD in relation to the severity of CD at begin of BoNT therapy (IMPQ). Then they had to draw the course of disease of CD from onset of symptoms until initiation of BoNT therapy (CoDB-graph) on a sheet of paper into a square of 10 x 10 cm(2) size. Remaining severity of CD was estimated by the treating physician using the TSUI-score. Demographical and treatment related data were extracted from the charts of the patients. Depending on the curvature four different types of CoDB-graphs could be distinguished. Time to BoNT therapy, increase of dose and improvement during BoNT treatment were significantly (p < 0.05) different when patients were split up according to CoDB-graph types. The lower the age at onset of symptoms, the shorter was the time to therapy (p < 0.02). Initial dose (p < 0.04) and actual dose (p < 0.009) were negatively correlated with the age of the patients at recruitment. The course of disease of CD before BoNT therapy has influence on long-term outcome. This has implications on patient management and information on the efficacy of BoNT treatment.
引用
收藏
页数:14
相关论文
共 50 条
[1]   Phenomenology and classification of dystonia: A consensus update [J].
Albanese, Alberto ;
Bhatia, Kailash ;
Bressman, Susan B. ;
DeLong, Mahlon R. ;
Fahn, Stanley ;
Fung, Victor S. C. ;
Hallett, Mark ;
Jankovic, Joseph ;
Jinnah, Hyder A. ;
Klein, Christine ;
Lang, Anthony E. ;
Mink, Jonathan W. ;
Teller, Jan K. .
MOVEMENT DISORDERS, 2013, 28 (07) :863-873
[2]   High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy [J].
Albrecht, Philipp ;
Jansen, Alexander ;
Lee, John-Ih ;
Moll, Marek ;
Ringelstein, Marius ;
Rosenthal, Dietmar ;
Bigalke, Hans ;
Aktas, Orhan ;
Hartung, Hans-Peter ;
Hefter, Harald .
NEUROLOGY, 2019, 92 (01) :E48-E54
[3]   Immunogenicity Associated with Botulinum Toxin Treatment [J].
Bellows, Steven ;
Jankovic, Joseph .
TOXINS, 2019, 11 (09)
[4]   A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia [J].
Benecke, R ;
Jost, WH ;
Kanovsky, P ;
Ruzicka, E ;
Comes, G ;
Grafe, S .
NEUROLOGY, 2005, 64 (11) :1949-1951
[5]  
Benecke R., 2003, Handbook of botulinum toxin treatment, P158
[6]  
Brashear A, 2000, MOVEMENT DISORD, V15, P150, DOI 10.1002/1531-8257(200001)15:1<150::AID-MDS1024>3.0.CO
[7]  
2-X
[8]   IDIOPATHIC CERVICAL DYSTONIA - CLINICAL CHARACTERISTICS [J].
CHAN, J ;
BRIN, MF ;
FAHN, S .
MOVEMENT DISORDERS, 1991, 6 (02) :119-126
[9]   Clinical Practice: evidence-Based Recommendations for the Treatment of Cervical Dystonia with Botulinum Toxin [J].
Contarino, Maria Fiorella ;
Van den Dool, Joost ;
Balash, Yacov ;
Bhatia, Kailash ;
Giladi, Nir ;
Koelman, Johannes H. ;
Lokkegaard, Annemette ;
Marti, Maria J. ;
Postma, Miranda ;
Relja, Maja ;
Skorvanek, Matej ;
Speelman, Johannes D. ;
Zoons, Evelien ;
Ferreira, Joaquim J. ;
Vidailhet, Marie ;
Albanese, Alberto ;
Tijssen, Marina A. J. .
FRONTIERS IN NEUROLOGY, 2017, 8
[10]   Clinical presentation and management of antibody-induced failure of botulinum toxin therapy [J].
Dressler, D .
MOVEMENT DISORDERS, 2004, 19 :S92-S100